Successful treatment of acute spleno-porto-mesenteric vein thrombosis after ChAdOx1 nCoV-19 vaccine. A case report

J Crit Care. 2021 Oct:65:72-75. doi: 10.1016/j.jcrc.2021.05.021. Epub 2021 Jun 4.

Abstract

Several cases of deep venous thrombosis in people who had recently received Vaxzevria (previously known as COVID-19 Vaccine AstraZeneca) have recently been reported, mainly presenting as cerebral vein/cerebral venous sinus thrombosis. This syndrome has been termed "vaccine-induced immune thrombotic thrombocytopenia (VITT)". Acute spleno-porto-mesenteric vein thrombosis is an uncommon but serious condition with potential sequelae, such as small-bowel gangrene and end-stage liver failure. We describe a case of concomitant thrombosis of portal, superior mesenteric and splenic veins in a young female patient with no other risk factors who received Vaxzevria (previously ChAdOx1 nCoV-19 vaccine, AstraZeneca) 17 days before. The diagnostic workup and the successful endovascular treatment and systemic anticoagulation management is reported.

Keywords: COVID-19 vaccine; Splanchnic thrombosis; Thrombocytopenia; Ultrasound-enhanced thrombolysis; VITT.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • ChAdOx1 nCoV-19
  • Female
  • Humans
  • Mesenteric Veins
  • SARS-CoV-2
  • Thrombosis*
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines
  • ChAdOx1 nCoV-19